scholarly journals Received dose variability after administration of I‐131 for treatment of hyperthyroidism in cats

2021 ◽  
Author(s):  
Suzanne Busser ◽  
Valerie J. Poirier ◽  
Carolyn Liggins ◽  
Sharyn Bray
Keyword(s):  
Dose Variability

scholarly journals Dose variability in different lymph node levels during locoregional breast cancer irradiation: the impact of deep-inspiration breath hold

2018 ◽  
Vol 195 (1) ◽  
pp. 13-20 ◽  
Author(s):  
Montserrat Pazos ◽  
Alba Fiorentino ◽  
Aurélie Gaasch ◽  
Stephan Schönecker ◽  
Daniel Reitz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Breath Hold ◽  
Deep Inspiration ◽  
Deep Inspiration Breath Hold ◽  
Dose Variability ◽  
The Impact ◽  
Cancer Irradiation

scholarly journals Anticoagulation in Atrial Fibrillation

2012 ◽  
Vol 1 ◽  
pp. 12 ◽  
Author(s):  
Yousif Ahmad ◽  
Gregory YH Lip ◽  
◽  
Keyword(s):  
Atrial Fibrillation ◽  
Oral Anticoagulants ◽  
Bleeding Risk ◽  
New Agents ◽  
Thromboembolic Risk ◽  
New Anticoagulants ◽  
Improved Outcomes ◽  
Proven Efficacy ◽  
Management Aspect ◽  
Dose Variability

Patients with atrial fibrillation (AF) are at increased thromboembolic risk, and they suffer more severe strokes with worse outcomes. Most thromboembolic complications of AF are eminently preventable with oral anticoagulation, and the increasing numbers of AF patients mean antithrombotic therapy is the most crucial management aspect of this common arrhythmia. Despite the proven efficacy of warfarin, a string of limitations have meant that it is underused by physicians and patients alike. This has prompted a search for new anticoagulants that could overcome many of the inconveniences of dose variability and anticoagulant monitoring associated with warfarin, but without sacrificing efficacy in thromboprophylaxis. The arrival of new oral anticoagulants has been complemented by improved risk stratification schemes, which permit clinicians to easily and reliably identify patients requiring anticoagulation and their bleeding risk. These advances in AF treatment will hopefully translate into improved outcomes for patients, especially as our experience with the new agents grows.

scholarly journals Multi‐site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos

2020 ◽  
Author(s):  
Nihal El Rouby ◽  
Leiliane Rodrigues Marcatto ◽  
Karla Claudio ◽  
Letícia Camargo Tavares ◽  
Heidi Steiner ◽  
...  
Keyword(s):  
Warfarin Dose ◽  
Site Investigation ◽  
Genetic Determinants ◽  
Dose Variability

scholarly journals EP-1772: Dose variability with breast tissue assignation for the INTRABEAM device

2018 ◽  
Vol 127 ◽  
pp. S950-S951
Author(s):  
P. Ibáñez ◽  
N. Pérez ◽  
P. Hinault ◽  
A. Villa-Araunza ◽  
J.M. Udías
Keyword(s):  
Breast Tissue ◽  
Dose Variability

scholarly journals Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups

Blood ◽  
2010 ◽  
Vol 115 (18) ◽  
pp. 3827-3834 ◽  
Author(s):  
Nita A. Limdi ◽  
Mia Wadelius ◽  
Larisa Cavallari ◽  
Niclas Eriksson ◽  
Dana C. Crawford ◽  
...  
Keyword(s):  
Linear Regression ◽  
Warfarin Dose ◽  
Population Level ◽  
Racial Groups ◽  
Nucleotide Polymorphisms ◽  
Single Nucleotide ◽  
Dose Prediction ◽  
Similar Dose ◽  
Warfarin Dosing ◽  
Dose Variability

Abstract Warfarin-dosing algorithms incorporating CYP2C9 and VKORC1 −1639G>A improve dose prediction compared with algorithms based solely on clinical and demographic factors. However, these algorithms better capture dose variability among whites than Asians or blacks. Herein, we evaluate whether other VKORC1 polymorphisms and haplotypes explain additional variation in warfarin dose beyond that explained by VKORC1 −1639G>A among Asians (n = 1103), blacks (n = 670), and whites (n = 3113). Participants were recruited from 11 countries as part of the International Warfarin Pharmacogenetics Consortium effort. Evaluation of the effects of individual VKORC1 single nucleotide polymorphisms (SNPs) and haplotypes on warfarin dose used both univariate and multi variable linear regression. VKORC1 −1639G>A and 1173C>T individually explained the greatest variance in dose in all 3 racial groups. Incorporation of additional VKORC1 SNPs or haplotypes did not further improve dose prediction. VKORC1 explained greater variability in dose among whites than blacks and Asians. Differences in the percentage of variance in dose explained by VKORC1 across race were largely accounted for by the frequency of the −1639A (or 1173T) allele. Thus, clinicians should recognize that, although at a population level, the contribution of VKORC1 toward dose requirements is higher in whites than in nonwhites; genotype predicts similar dose requirements across racial groups.

Breast Dose Variability in a Bi-racial Population Undergoing Screening Mammography

2002 ◽  
Vol 98 (4) ◽  
pp. 417-424
Author(s):  
M. K. Schubauer-Berigan ◽  
L. Baron ◽  
G. D. Frey ◽  
D. G. Hoel
Keyword(s):  
Screening Mammography ◽  
Dose Variability

scholarly journals Trends in erythemal doses at the Polish Polar Station, Hornsund, Svalbard based on the homogenized measurements (1996–2016) and reconstructed data (1983–1995)

2018 ◽  
Vol 18 (1) ◽  
pp. 1-11 ◽  
Author(s):  
Janusz W. Krzyścin ◽  
Piotr S. Sobolewski
Keyword(s):  
Historical Data ◽  
Sunshine Duration ◽  
Satellite Measurements ◽  
Data Set ◽  
Modification Factor ◽  
Daily Sunshine ◽  
Yearly Dose ◽  
Column Ozone ◽  
Dose Variability

Abstract. Erythemal daily doses measured at the Polish Polar Station, Hornsund (77°00′ N, 15°33′ E), for the periods 1996–2001 and 2005–2016 are homogenized using yearly calibration constants derived from the comparison of observed doses for cloudless conditions with the corresponding doses calculated by radiative transfer (RT) simulations. Modeled all-sky doses are calculated by the multiplication of cloudless RT doses by the empirical cloud modification factor dependent on the daily sunshine duration. An all-sky model is built using daily erythemal doses measured in the period 2005–2006–2007. The model is verified by comparisons with the 1996–1997–1998 and 2009–2010–2011 measured data. The daily doses since 1983 (beginning of the proxy data) are reconstructed using the all-sky model with the historical data of the column ozone from satellite measurements (SBUV merged ozone data set), the snow depth (for ground albedo estimation), and the observed daily sunshine duration at the site. Trend analyses of the monthly and yearly time series comprised of the reconstructed and observed doses do not reveal a statistically significant trend in the period 1983–2016. The trends based on the observed data only (1996–2001 and 2005–2016) show declining tendency (about −1 % per year) in the monthly mean of daily erythemal doses in May and June, and in the yearly sum of daily erythemal doses. An analysis of sources of the yearly dose variability since 1983 shows that cloud cover changes are a basic driver of the long-term UV changes at the site.

Factors causing dose variability in drug administration

1989 ◽  
Vol 24 (6) ◽  
Author(s):  
Romano Demicheli ◽  
Antonio Jirillo ◽  
Giorgio Bonciarelli ◽  
Federico Lonardi ◽  
Marco Pradella ◽  
...  
Keyword(s):  
Drug Administration ◽  
Dose Variability

scholarly journals Evaluation of Factors That Influence Dose Variability of Marek's Disease Vaccines

2019 ◽  
Vol 63 (4) ◽  
pp. 591
Author(s):  
B. A. López de Juan Abad ◽  
A. L. Cortes ◽  
M. Correa ◽  
I. M. Gimeno
Keyword(s):  
Marek's Disease ◽  
Marek’S Disease ◽  
Dose Variability

Haematological drugs

2011 ◽  
Author(s):  
Carl Waldmann ◽  
Neil Soni ◽  
Andrew Rhodes
Keyword(s):  
Side Effects ◽  
Vitamin K Antagonists ◽  
Therapeutic Window ◽  
Bleeding Complications ◽  
Therapeutic Drug ◽  
Oral Vitamin ◽  
Heparin Induced Thrombocytopenia ◽  
Therapeutic Anticoagulation ◽  
High Incidence ◽  
Dose Variability

Anticoagulants and heparin-induced thrombocytopenia 220Thrombolysis 224Antifibrinolytics 226For >50 years, the options for therapeutic anticoagulation were limited to unfractionated heparin (UFH) and oral vitamin K antagonists. While highly effective, both drugs have major safety problems. Both have narrow therapeutic ranges, substantial interindividual dose variability, major side effects and require regular therapeutic drug monitoring, with a narrow therapeutic window and high incidence of bleeding complications....

Sign in / Sign up

Export Citation Format

Share Document